Asaad, H.M., Hassanin, O., Saif-Edin, M. et al. The impact of innate and humoral immune mechanisms on vaccine induced protection against avian influenza H9N2 in broilers. Sci Rep 15, 43016 (2025)
Avian influenza virus (AIV) (H9N2) is a highly contagious avian respiratory disease that causes significant economic losses in the poultry industry sector. Although immunological responses to AIV (H9N2) vaccinations have been extensively studied, little is known about how inactivated vaccines interact with the host’s innate and adaptive immune responses. Five commercially available inactivated avian influenza virus (AIV) H9N2 vaccines, each containing different virus strains and adjuvant compositions, were administered via subcutaneous injection to 4-day-old commercial broiler chicks. The effects of vaccination on the kinetics of chicken toll-like receptor (TLR) 5 and 7 pathways, along with their downstream cytokines and the expression profiles of major histocompatibility complex class I and 2 (MHC-1 and 2) expression profiles were investigated. Quantitative real-time PCR analysis demonstrated that immunization with inactivated H9N2 AIV vaccines activated pattern recognition receptors (PRRs), specifically TLR-5 and TLR-7, along with their downstream cytokines. These included the proinflammatory interleukin-6 (IL-6), antiviral interferon-alpha, and myxoma resistance protein 1 (Mx1). This activation was observed as early as 48 h post-vaccination and persisted for up to 7 days in the spleens of the vaccinated birds. Subcutaneous administration of either inactivated vaccine A or B elicited the highest expression levels of IL-6, MHC class I, and MHC-1 and MHC-2 molecules. Hemagglutination-inhibition (HI) antibody titers against avian influenza were?>?5 log2 from two to five weeks post-vaccination, with vaccine A inducing significantly higher responses at weeks three, four, and five. Following intraocular challenge with 106 EID50/ml of a locally isolated avian influenza virus strain, vaccines A, B, and E conferred complete (100%) protection against mortality. Notably, vaccine A demonstrated superior clinical protection and resulted in minimal histopathological lesions in the tracheal and pulmonary tissues.
See Also:
Latest articles in those days:
- The evolution and transmission dynamics of H3N2 influenza virus identified in a respiratory disease outbreak in companion dogs in Alabama, USA 6 hours ago
- Structural and functional characterization of hemagglutinin E190D and Q226H minor variants in human H5N1 A/British Columbia/PHL-2032/2024 6 hours ago
- Spatial risk factors associated with outbreaks of highly pathogenic avian influenza in Pennsylvania’s commercial poultry farms 7 hours ago
- [preprint]H9N2 avian influenza virus in Bangladesh: three genetically distinct co-circulating subgroups retain a largely conserved antigenic phenotype 7 hours ago
- [preprint]Endogenous serine proteases in MDCK sublines support trypsin-independent influenza A virus replication 7 hours ago
[Go Top] [Close Window]


